Abstract
Malignant gliomas are common primary tumors of the central nervous system, characterized by aggressive cell proliferation, diffuse infiltration and resistance to conventional therapy. Glioblastoma (former Glioblastoma multiforme, GBM), grade IV astrocytoma, is the most aggressive tumor, with a median survival of around 14 months. New therapies against this devastating and invariably fatal disease are needed. Stem-like cell populations have been identified in a number of malignancies including glioblastoma. These rare stem cells (called also glioma-initiating cells) are believed to be responsible not only for tumor initiation and progression but also resistance to therapeutic agents and tumor recurrence. Recently, the population of cells within glioblastoma with stem-like properties has gained increasing attention as a target to refine treatment strategies. This chapter aims to summarize the recent data regarding isolation, biology and mechanisms of resistance of glioblastoma stem-like cells to therapy.
Keywords: Glioblastoma, glioma-initiating cells (GIC), glioma stem cells (GSC), functional characteristics, isolation, markers, therapeutic resistance.
Current Signal Transduction Therapy
Title:Glioblastoma Stem-Like Cells – Isolation, Biology and Mechanisms of Chemotherapy Resistance
Volume: 8 Issue: 3
Author(s): Iwona Anna Ciechomska, Marta Kocyk and Bozena Kaminska
Affiliation:
Keywords: Glioblastoma, glioma-initiating cells (GIC), glioma stem cells (GSC), functional characteristics, isolation, markers, therapeutic resistance.
Abstract: Malignant gliomas are common primary tumors of the central nervous system, characterized by aggressive cell proliferation, diffuse infiltration and resistance to conventional therapy. Glioblastoma (former Glioblastoma multiforme, GBM), grade IV astrocytoma, is the most aggressive tumor, with a median survival of around 14 months. New therapies against this devastating and invariably fatal disease are needed. Stem-like cell populations have been identified in a number of malignancies including glioblastoma. These rare stem cells (called also glioma-initiating cells) are believed to be responsible not only for tumor initiation and progression but also resistance to therapeutic agents and tumor recurrence. Recently, the population of cells within glioblastoma with stem-like properties has gained increasing attention as a target to refine treatment strategies. This chapter aims to summarize the recent data regarding isolation, biology and mechanisms of resistance of glioblastoma stem-like cells to therapy.
Export Options
About this article
Cite this article as:
Ciechomska Anna Iwona, Kocyk Marta and Kaminska Bozena, Glioblastoma Stem-Like Cells – Isolation, Biology and Mechanisms of Chemotherapy Resistance, Current Signal Transduction Therapy 2013; 8 (3) . https://dx.doi.org/10.2174/1574362409666140206223501
DOI https://dx.doi.org/10.2174/1574362409666140206223501 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Oxaliplatin-mediated Inhibition of Survivin Increases Sensitivity of Head and Neck Squamous Cell Carcinoma Cell Lines to Paclitaxel
Current Cancer Drug Targets Dendritic Cells in Esophageal Adenocarcinoma: The Currently Available Information and Possibilities to use Dendritic Cells for Immunotherapeutic Approaches
Current Pharmaceutical Design Current and Future Drug Treatments for Glioblastomas
Current Medicinal Chemistry Diffuse Intrinsic Pontine Glioma: New Pathophysiological Insights and Emerging Therapeutic Targets
Current Neuropharmacology Editorial (Hot Topic: Targeted Therapy of Malignant Brain Tumors)
Current Signal Transduction Therapy Encapsulation of Imatinib in Targeted KIT-5 Nanoparticles for Reducing its Cardiotoxicity and Hepatotoxicity
Anti-Cancer Agents in Medicinal Chemistry Role of the RAS in Pancreatic Cancer
Current Cancer Drug Targets The Role of Non-coding Genome in Cancer-associated Fibroblasts; Stateof- the-Art and Perspectives in Cancer Targeted Therapy
Current Drug Targets Epithelial-Mesenchymal Transition: Implications in Cancer Progression and Metastasis
Current Pharmaceutical Biotechnology The Role of XRCC4 in Carcinogenesis and Anticancer Drug Discovery
Recent Patents on Anti-Cancer Drug Discovery Meet Our Associate Editorial Board Member
Current Drug Delivery Cutaneous Melanoma: A Test Field for Immunotherapy and a Medical Challenge
Current Cancer Therapy Reviews Recent Advances in the Mitsunobu Reaction: Modifications and Applications to Biologically Active Molecules
Current Organic Chemistry Oxazole-Based Compounds As Anticancer Agents
Current Medicinal Chemistry Targeted Radiosensitization in Prostate Cancer
Current Pharmaceutical Design Cell Cycle as a Target of Antineoplastic Drugs
Current Pharmaceutical Design Selected Approaches for Rational Drug Design and High Throughput Screening to Identify Anti-Cancer Molecules
Anti-Cancer Agents in Medicinal Chemistry Relevance of Breast Cancer Resistance Protein to Brain Distribution and Central Acting Drugs: A Pharmacokinetic Perspective
Current Drug Metabolism Targeting the Brain: Advances in Drug Delivery
Current Pharmaceutical Biotechnology Irreversible Multitargeted ErbB Family Inhibitors for Therapy of Lung and Breast Cancer
Current Cancer Drug Targets